Cargando…

Serum Aberrant N-Glycan Profile as a Marker Associated with Early Antibody-Mediated Rejection in Patients Receiving a Living Donor Kidney Transplant

We determined if the serum N-glycan profile can be used as a diagnostic marker of antibody-mediated rejection (ABMR) in living donor kidney transplant (LKTx) recipients. Glycoblotting, combined with mass spectrometry, was used to retrospectively examine N-glycan levels in the postoperative sera of 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Noro, Daisuke, Yoneyama, Tohru, Hatakeyama, Shingo, Tobisawa, Yuki, Mori, Kazuyuki, Hashimoto, Yasuhiro, Koie, Takuya, Tanaka, Masakazu, Nishimura, Shin-Ichiro, Sasaki, Hideo, Saito, Mitsuru, Harada, Hiroshi, Chikaraishi, Tatsuya, Ishida, Hideki, Tanabe, Kazunari, Satoh, Shigeru, Ohyama, Chikara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578121/
https://www.ncbi.nlm.nih.gov/pubmed/28786963
http://dx.doi.org/10.3390/ijms18081731
_version_ 1783260474097270784
author Noro, Daisuke
Yoneyama, Tohru
Hatakeyama, Shingo
Tobisawa, Yuki
Mori, Kazuyuki
Hashimoto, Yasuhiro
Koie, Takuya
Tanaka, Masakazu
Nishimura, Shin-Ichiro
Sasaki, Hideo
Saito, Mitsuru
Harada, Hiroshi
Chikaraishi, Tatsuya
Ishida, Hideki
Tanabe, Kazunari
Satoh, Shigeru
Ohyama, Chikara
author_facet Noro, Daisuke
Yoneyama, Tohru
Hatakeyama, Shingo
Tobisawa, Yuki
Mori, Kazuyuki
Hashimoto, Yasuhiro
Koie, Takuya
Tanaka, Masakazu
Nishimura, Shin-Ichiro
Sasaki, Hideo
Saito, Mitsuru
Harada, Hiroshi
Chikaraishi, Tatsuya
Ishida, Hideki
Tanabe, Kazunari
Satoh, Shigeru
Ohyama, Chikara
author_sort Noro, Daisuke
collection PubMed
description We determined if the serum N-glycan profile can be used as a diagnostic marker of antibody-mediated rejection (ABMR) in living donor kidney transplant (LKTx) recipients. Glycoblotting, combined with mass spectrometry, was used to retrospectively examine N-glycan levels in the postoperative sera of 197 LKTx recipients of whom 16 recipients had ABMR with or without T-cell-mediated rejection (TCMR), 40 recipients had TCMR, and 141 recipients had no adverse events. Multivariate discriminant analysis for prediction of ABMR was performed by inputting an ABMR event as an explanatory variable and sex, age, and serum N-glycan level as objective variables. The N-glycan score was calculated by multiplying the level of candidate objective variables by objective function values. The ABMR predictive performance of the N-glycan score was assessed by receiver operator characteristic curve and Kaplan–Meier curve analyses. The N-glycan score discriminated ABMR with 81.25% sensitivity, 87.85% specificity, and an area under the curve (AUC) of 0.892 that was far superior to that of preformed donor-specific antibody status (AUC, 0.761). Recipients with N-glycan-positive scores >0.8770 had significantly shorter ABMR survival than that of recipients with N-glycan-negative scores. Although the limitations of our study includ its small sample size and retrospective nature, the serum N-glycan score may contribute to prediction of ABMR.
format Online
Article
Text
id pubmed-5578121
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-55781212017-09-05 Serum Aberrant N-Glycan Profile as a Marker Associated with Early Antibody-Mediated Rejection in Patients Receiving a Living Donor Kidney Transplant Noro, Daisuke Yoneyama, Tohru Hatakeyama, Shingo Tobisawa, Yuki Mori, Kazuyuki Hashimoto, Yasuhiro Koie, Takuya Tanaka, Masakazu Nishimura, Shin-Ichiro Sasaki, Hideo Saito, Mitsuru Harada, Hiroshi Chikaraishi, Tatsuya Ishida, Hideki Tanabe, Kazunari Satoh, Shigeru Ohyama, Chikara Int J Mol Sci Article We determined if the serum N-glycan profile can be used as a diagnostic marker of antibody-mediated rejection (ABMR) in living donor kidney transplant (LKTx) recipients. Glycoblotting, combined with mass spectrometry, was used to retrospectively examine N-glycan levels in the postoperative sera of 197 LKTx recipients of whom 16 recipients had ABMR with or without T-cell-mediated rejection (TCMR), 40 recipients had TCMR, and 141 recipients had no adverse events. Multivariate discriminant analysis for prediction of ABMR was performed by inputting an ABMR event as an explanatory variable and sex, age, and serum N-glycan level as objective variables. The N-glycan score was calculated by multiplying the level of candidate objective variables by objective function values. The ABMR predictive performance of the N-glycan score was assessed by receiver operator characteristic curve and Kaplan–Meier curve analyses. The N-glycan score discriminated ABMR with 81.25% sensitivity, 87.85% specificity, and an area under the curve (AUC) of 0.892 that was far superior to that of preformed donor-specific antibody status (AUC, 0.761). Recipients with N-glycan-positive scores >0.8770 had significantly shorter ABMR survival than that of recipients with N-glycan-negative scores. Although the limitations of our study includ its small sample size and retrospective nature, the serum N-glycan score may contribute to prediction of ABMR. MDPI 2017-08-08 /pmc/articles/PMC5578121/ /pubmed/28786963 http://dx.doi.org/10.3390/ijms18081731 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Noro, Daisuke
Yoneyama, Tohru
Hatakeyama, Shingo
Tobisawa, Yuki
Mori, Kazuyuki
Hashimoto, Yasuhiro
Koie, Takuya
Tanaka, Masakazu
Nishimura, Shin-Ichiro
Sasaki, Hideo
Saito, Mitsuru
Harada, Hiroshi
Chikaraishi, Tatsuya
Ishida, Hideki
Tanabe, Kazunari
Satoh, Shigeru
Ohyama, Chikara
Serum Aberrant N-Glycan Profile as a Marker Associated with Early Antibody-Mediated Rejection in Patients Receiving a Living Donor Kidney Transplant
title Serum Aberrant N-Glycan Profile as a Marker Associated with Early Antibody-Mediated Rejection in Patients Receiving a Living Donor Kidney Transplant
title_full Serum Aberrant N-Glycan Profile as a Marker Associated with Early Antibody-Mediated Rejection in Patients Receiving a Living Donor Kidney Transplant
title_fullStr Serum Aberrant N-Glycan Profile as a Marker Associated with Early Antibody-Mediated Rejection in Patients Receiving a Living Donor Kidney Transplant
title_full_unstemmed Serum Aberrant N-Glycan Profile as a Marker Associated with Early Antibody-Mediated Rejection in Patients Receiving a Living Donor Kidney Transplant
title_short Serum Aberrant N-Glycan Profile as a Marker Associated with Early Antibody-Mediated Rejection in Patients Receiving a Living Donor Kidney Transplant
title_sort serum aberrant n-glycan profile as a marker associated with early antibody-mediated rejection in patients receiving a living donor kidney transplant
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578121/
https://www.ncbi.nlm.nih.gov/pubmed/28786963
http://dx.doi.org/10.3390/ijms18081731
work_keys_str_mv AT norodaisuke serumaberrantnglycanprofileasamarkerassociatedwithearlyantibodymediatedrejectioninpatientsreceivingalivingdonorkidneytransplant
AT yoneyamatohru serumaberrantnglycanprofileasamarkerassociatedwithearlyantibodymediatedrejectioninpatientsreceivingalivingdonorkidneytransplant
AT hatakeyamashingo serumaberrantnglycanprofileasamarkerassociatedwithearlyantibodymediatedrejectioninpatientsreceivingalivingdonorkidneytransplant
AT tobisawayuki serumaberrantnglycanprofileasamarkerassociatedwithearlyantibodymediatedrejectioninpatientsreceivingalivingdonorkidneytransplant
AT morikazuyuki serumaberrantnglycanprofileasamarkerassociatedwithearlyantibodymediatedrejectioninpatientsreceivingalivingdonorkidneytransplant
AT hashimotoyasuhiro serumaberrantnglycanprofileasamarkerassociatedwithearlyantibodymediatedrejectioninpatientsreceivingalivingdonorkidneytransplant
AT koietakuya serumaberrantnglycanprofileasamarkerassociatedwithearlyantibodymediatedrejectioninpatientsreceivingalivingdonorkidneytransplant
AT tanakamasakazu serumaberrantnglycanprofileasamarkerassociatedwithearlyantibodymediatedrejectioninpatientsreceivingalivingdonorkidneytransplant
AT nishimurashinichiro serumaberrantnglycanprofileasamarkerassociatedwithearlyantibodymediatedrejectioninpatientsreceivingalivingdonorkidneytransplant
AT sasakihideo serumaberrantnglycanprofileasamarkerassociatedwithearlyantibodymediatedrejectioninpatientsreceivingalivingdonorkidneytransplant
AT saitomitsuru serumaberrantnglycanprofileasamarkerassociatedwithearlyantibodymediatedrejectioninpatientsreceivingalivingdonorkidneytransplant
AT haradahiroshi serumaberrantnglycanprofileasamarkerassociatedwithearlyantibodymediatedrejectioninpatientsreceivingalivingdonorkidneytransplant
AT chikaraishitatsuya serumaberrantnglycanprofileasamarkerassociatedwithearlyantibodymediatedrejectioninpatientsreceivingalivingdonorkidneytransplant
AT ishidahideki serumaberrantnglycanprofileasamarkerassociatedwithearlyantibodymediatedrejectioninpatientsreceivingalivingdonorkidneytransplant
AT tanabekazunari serumaberrantnglycanprofileasamarkerassociatedwithearlyantibodymediatedrejectioninpatientsreceivingalivingdonorkidneytransplant
AT satohshigeru serumaberrantnglycanprofileasamarkerassociatedwithearlyantibodymediatedrejectioninpatientsreceivingalivingdonorkidneytransplant
AT ohyamachikara serumaberrantnglycanprofileasamarkerassociatedwithearlyantibodymediatedrejectioninpatientsreceivingalivingdonorkidneytransplant